RapidAI obtains Class III Shonin clearance in Japan for stroke imaging and introduces Rapid Edge Cloud, a hybrid platform ensuring AI accessibility offline. The California-based health tech company’s new non-contrast CT offering aids initial stroke identification. CEO Karim Karti highlights the innovation’s role in expanding disease state coverage. Previously securing substantial funding, RapidAI continues its international expansion, leveraging AI for stroke assessment alongside its FDA-cleared solutions in pulmonary embolism and brain injury diagnosis.
RapidAI, a health tech company specializing in imaging analysis software, announced it received Class III Shonin clearance in Japan and launched a hybrid technology platform, Rapid Edge Cloud, and a non-contrast CT offering for stroke identification.
RapidAI offers numerous imaging solutions for stroke, aneurysm and pulmonary embolism. It also provides technology platforms to enable coordinated care between hospital care teams and EMS providers, analytics software to help hospitals operationally and a clinical trial platform to help streamline the clinical trial screening and enrollment process.
The company received clearance for its MR-based stroke imaging platform to support mechanical thrombectomy determination in Japan, expanding its reach internationally.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
It also announced the launch of Rapid Edge Cloud, a hybrid cloud and on-site technology platform built to allow on-premises healthcare providers continued access to AI services should a hospital need to cut off its cloud connectivity.
The California-based company also announced its non-contrast CT offering to help identify stroke within the first scans.
“While celebrating a year of significant achievements, we have also been working tirelessly behind the scenes to prepare for the next phase of innovation and expansion into new disease states,” Karim Karti, CEO of RapidAI, said in a statement. “Our breakthrough AI, cutting-edge approach and Edge Cloud technology platform will take clinical decision support deeper than ever before and play a crucial role in transforming the landscape of care across diseases.”
THE LARGER TREND
RapidAI scored $75 million in Series C funding in July.
In 2020, it secured $25 million in a Series B round and acquired cerebral aneurysm management platform EndoVantage.
RapidAI, also known as iSchemaView, has received considerable FDA 510(k) clearances in the U.S., most recently for Rapid SDH, a radiological computer-assisted triage and notification software.
Other offerings with 510(k) clearance include:
- Rapid RV/LV, which aims to speed up the pulmonary embolism triage and care process.
- Rapid ASPECTS device, which assists physicians in detecting brain injuries and determining if a patient is eligible for a thrombectomy.
- Rapid Hyperdensity, which allows physicians to assess the severity of injury in patients with acute neurological conditions like brain hemorrhages and traumatic brain injury.
The company already had an international presence, including in the National University Hospital (NUH) in Singapore and throughout Latin America.
Another company utilizing AI to evaluate stroke is British medtech company Brainomix, which earlier this year received FDA clearance for its AI-enabled stroke software Brainomix 360 e-ASPECTS, used to measure the extent of early ischemic changes or a reduction or restriction of blood flow in the brain of stroke patients.
Source: Mobihealth News
